Recent Annual Reports

Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.

📊 4797 Reports

🤖 AI Analyzed

Recent

📄 Page 234 of 400

Corvus Pharmaceuticals, Inc.

10-K March 12, 2026

Key Highlights

Initial Phase 2 data for soquelitinib in T-cell lymphomas expected mid-2026, a s...
Strong cash position of $75.3 million as of December 31, 2025, providing an esti...
Advancing a diverse pipeline including soquelitinib (oncology/autoimmune), cifor...

Read Analysis

🤖 AI Generated

COMM 2015-LC19 Mortgage Trust

10-K March 12, 2026

Key Highlights

Operates as a CMBS trust, distributing payments from commercial mortgage loans t...
Maintains diversification with no single borrower representing 10% or more of th...
Performance is directly tied to the underlying commercial mortgage loans, withou...

Read Analysis

🤖 AI Generated

Health Catalyst, Inc.

10-K March 12, 2026

Key Highlights

Solid 7.1% total revenue growth to $300 million in 2025, driven by both technolo...
Strong recurring technology revenue grew to $170 million in 2025, representing 9...
Aggressive market expansion through four strategic acquisitions in 2024-2025, ai...

Read Analysis

🤖 AI Generated

OnKure Therapeutics, Inc.

10-K March 12, 2026

Key Highlights

Clinical-stage biotech focused on developing new cancer treatments for unmet med...
Lead drug candidate, OKI-219, is currently in Phase 2 clinical trials.
Proposed merger agreement with Reneo Pharmaceuticals, Inc. announced on October ...

Read Analysis

🤖 AI Generated

DUKE Robotics Corp.

10-K March 12, 2026

Key Highlights

Successful strategic shift to advanced robotics with validated defense and civil...
TIKAD defense system actively deployed by IDF, demonstrating real-world combat e...
Secured and extended commercial agreement with IEC, ensuring stable revenue in c...

Read Analysis

🤖 AI Generated

Bolt Biotherapeutics, Inc.

10-K March 12, 2026

Key Highlights

Developing innovative cancer immunotherapies using a proprietary platform of tum...
Pipeline features drug candidates in various stages, addressing specific cancer ...
Operates as both a "Smaller reporting company" and an "Emerging growth company,"...

Read Analysis

🤖 AI Generated

SANTANDER UK GROUP HOLDINGS PLC

20-F March 12, 2026

Key Highlights

Santander UK reported solid performance for FY2023 with an 8% revenue increase a...
The bank maintains a robust financial position with a CET1 ratio of 14.8% and an...
Digital adoption accelerated, with 70% of customer interactions now occurring di...

Read Analysis

🤖 AI Generated

COMM 2015-CCRE27 Mortgage Trust

10-K March 12, 2026

Key Highlights

Operates as a Commercial Mortgage-Backed Securities (CMBS) Trust, generating inc...
Compliance with SEC reporting requirements confirmed for the fiscal year ended D...
Initial diversification with no single borrower representing more than 10% of to...

Read Analysis

🤖 AI Generated

Runway Growth Finance Corp.

10-K March 12, 2026

Key Highlights

Empowers high-growth, late-stage companies with crucial debt financing and strat...
Total investment portfolio valued at $927.4 million as of December 31, 2025, wit...
External manager, Runway Growth Capital LLC (RGC), was acquired by BC Partners i...

Read Analysis

🤖 AI Generated

Velocity Financial, Inc.

10-K March 12, 2026

Key Highlights

Specializes in real estate finance, originating and managing loans for experienc...
Focuses on the business purpose loan market, backed by 1-4 unit residential and ...
Generates income through diverse streams including loan interest and gains from ...

Read Analysis

🤖 AI Generated

VITASPRING BIOMEDICAL CO. LTD.

10-K March 12, 2026

Key Highlights

Proprietary X.msc and X.exosome technology in cellular and regenerative medicine...
Award-winning R&D team with 'mass-production know-how' for stem cell processing.
Operates in the rapidly growing global regenerative medicine market, estimated t...

Read Analysis

🤖 AI Generated

GRAIL, Inc.

10-K March 12, 2026

Key Highlights

Robust 25% revenue growth in 2025, reaching $200 million, driven by both screeni...
Pioneering multi-cancer early detection (MCED) technology with Galleri, addressi...
Significant R&D investment ($300 million in 2025) demonstrates commitment to inn...

Read Analysis

🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.

Back to Homepage